☰

Todd A. Triplett - Publications

Affiliations: 
University of Texas at Austin, Austin, Texas, U.S.A. 
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. Frontiers in Immunology. 14: 1260545. PMID 37744352 DOI: 10.3389/fimmu.2023.1260545  0.533
2020 Lyu A, Triplett TA, Nam SH, Hu Z, Arasappan D, Godfrey WH, Ames RY, Sarang A, Selden HJ, Lee CH, Georgiou G, Horton TM, Ehrlich LIR. Tumor-associated myeloid cells provide critical support for T-ALL. Blood. PMID 32845007 DOI: 10.1182/Blood.2020007145  0.655
2020 Bloom MJ, Jarrett AM, Triplett TA, Syed AK, Davis T, Yankeelov TE, Sorace AG. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer. Bmc Cancer. 20: 359. PMID 32345237 DOI: 10.1186/S12885-020-06868-4  0.302
2020 Warden AS, Triplett TA, Lyu A, Grantham EK, Azzam MM, DaCosta A, Mason S, Blednov YA, Ehrlich LIR, Mayfield RD, Harris RA. Microglia depletion and alcohol: Transcriptome and behavioral profiles. Addiction Biology. e12889. PMID 32176824 DOI: 10.1111/Adb.12889  0.671
2019 Bloom M, Jarrett A, Triplett T, Syed A, Yankeelov T, Sorace A. Abstract P4-06-17: Investigating trastuzumab-induced myeloid cell alterations for improving combination therapy in HER2+ breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-06-17  0.426
2019 Bloom MJ, Jarrett AM, Triplett TA, Syed AK, Yankeelov TE, Sorace AG. Abstract 187: Trastuzumab induced myeloid cell alterations identifies mechanistic properties of vascular normalization Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-187  0.329
2019 Miljanic M, Holay N, Capasso A, Triplett T, Soleimani M, Giri U, Berg CVD, Eckhardt G. Abstract 4753: Attenuating colorectal cancer cell growth and enhancing immunogenicity through rational combination of MEK and HDAC inhibition Cancer Research. 79: 4753-4753. DOI: 10.1158/1538-7445.Am2019-4753  0.48
2018 Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology. PMID 30010674 DOI: 10.1038/Nbt.4180  0.477
2017 Triplett TA, Triplett K, Stone E, Zhang M, Manfredi M, Lamb C, Tanno Y, Ehrlich L, Georgiou G. Abstract 5571: Immune-checkpoint inhibition via enzyme-mediated degradation of kynurenine Cancer Research. 77: 5571-5571. DOI: 10.1158/1538-7445.Am2017-5571  0.768
2017 Zhang M, Stone E, Triplett TA, Triplett K, Lamb C, Karamitros CS, Blazek J, Georgiou G, Manfredi MG. Abstract 5570: A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine Cancer Research. 77: 5570-5570. DOI: 10.1158/1538-7445.Am2017-5570  0.502
2017 Triplett TA, Lyu A, Godfrey W, Ehrlich LIE. Abstract 2965: Myeloid depletion reverses established T-ALL growthin vivo Cancer Research. 77: 2965-2965. DOI: 10.1158/1538-7445.Am2017-2965  0.747
2016 Triplett TA, Cardenas KT, Lancaster JN, Hu Z, Selden HJ, Jasso GJ, Balasubramanyam S, Chan K, Li L, Chen X, Marcogliese AN, Davé UP, Love PE, Ehrlich LI. Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proceedings of the National Academy of Sciences of the United States of America. PMID 26862168 DOI: 10.1073/Pnas.1520245113  0.663
2015 Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade. Cancer Immunology Research. 3: 526-35. PMID 25627655 DOI: 10.1158/2326-6066.CIR-14-0187  0.574
2015 Triplett TA, Cardenas KT, Jones JN, Selden HJ, Jasso GJ, Balasubramanyam S, Hu Z, LiQi L, Love PE, Ehrlich LI. Abstract A02: Altered myeloid cells in the tumor microenvironment promote growth of T cell acute lymphoblastic leukemia. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A02  0.821
2015 Stone E, Marshall N, Donkor M, Triplett K, Blazek J, Triplett T, Ehrlich L, Georgiou G. Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-226  0.747
2013 Akporiaye ET, Tucker C, Triplett T, Garrison K, Sun L, Ling L, Weinberg A. STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P68  0.631
2012 Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. European Journal of Immunology. 42: 1893-905. PMID 22585674 DOI: 10.1002/Eji.201242444  0.354
Show low-probability matches.